European Perspectives

UBC - December 20, 2013
On behalf of the entire UBC team, we wish you a wonderful holiday season. This past year has been filled with opportunities to collaborate with you and support your products and patients.  We appreciate your trust in us, and we...
Tagged in:
UBC - December 17, 2013
The past twelve months have brought change, and with it, new opportunity. In our last blog post of 2013, we want to take a moment to reflect on our accomplishments and share with our readers some highlights from this past year:...
UBC - December 12, 2013
In Patrick Lindsay’s recent interview with Pharmaceutical Executive magazine he was very frank about his position on talent, saying, “… our greatest asset is people. I spend a good part of every waking moment thinking how do I attract...
Tagged in:
UBC - December 06, 2013
In order for biopharmaceutical companies to gain product approval, regulatory agencies first require a series of risk evaluations. Clinical trials, for example, may be utilized in the early phases of development in order to prove a...
UBC - November 27, 2013
Time and Motion studies are an appropriate solution when the efficiency of a drug, medical device, or intervention is the outcome of interest. In the current environment of more stringent evidence requirements by regulators and payers...

Pages